Loading
A phase 1/2 trial of U32 CAR-T in acute myeloid leukaemia, run by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, now recruiting.
Clinical Study of U32 in Patients With Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT07036250 by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, with 20 participants planned, started 2025-07-03 and due to reach its primary completion in 2027-12-31. Interventions recorded: U32 CAR-T.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Unicar-Therapy and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares CAR-T cell therapy and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/